Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer.
نویسندگان
چکیده
PURPOSE Overtreatment of screen-detected localized prostate cancer (LPC) is an important public health concern, since the survival benefit of aggressive treatment (surgery or radiation) has not been well established. We investigated the survival expectations of patients who had LPC with and without their chosen treatment. METHODS A population-based sample of 260 men (132 black, 128 white) 75 years old or younger with newly diagnosed LPC completed a self-administered survey. How long the patients expected to live with their chosen treatment, how long they would expect to live with no treatment, and factors associated with the difference in perceived life expectancy were assessed using multivariable analysis. RESULTS Without any treatment, 33% of patients expected that they would live less than 5 years, 41% 5 to 10 years, 21% 10 to 20 years, and 5% more than 20 years. With their chosen treatment, 3% of patients expected to live less than 5 years, 9% 5 to 10 years, 33% 10 to 20 years, and 55% more than 20 years. Treatment chosen, age, general health perception, and perceived cancer seriousness predicted the differences in perceived life expectancy, while race and actual tumor risk did not. After adjustment for other covariates, men who choose surgery or radiation expected greater gain in survival than men who chose watchful waiting or active surveillance. CONCLUSIONS Most patients with LPC underestimated their life expectancy without treatment and overestimated the gain in life expectancy with surgery or radiation. These unrealistic expectations may compromise patients' ability to make informed treatment decisions and may contribute to overtreatment of LPC. Primary care physicians, when included in the decision process, should focus on helping patients develop realistic expectations and choices that support their treatment goals.
منابع مشابه
PSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملمقایسه مدل کاکس و مدل های پارامتری در برآورد بقاء درمان مبتلایان سرطان پروستات تحت رادیوتراپی
Background and purpose: Prostate cancer is the second most common malignant cancer in men and radiotherapy is one of the treatments for this disease. The aim of this study was to determine the effect of demographic, clinical and pathology factors in survival rate of patients on radiotherapy and comparing different survival models to determine an efficient model. Materials and methods: In a his...
متن کاملA review on the role of oral ginseng on erection dysfunction and fatigue in prostate cancer patients
Background: Current pharmacological and non-pharmacological treatment strategies for prostate cancer may control disease progression and increase the survival rates of patients but decreased quality of life is the most important concern of existing medical interventions. Erection dysfunction and fatigue are the most prevalent adverse effects of therapeutic procedures which impair the qual...
متن کاملPatients' survival expectations before localized prostate cancer treatment by treatment status.
BACKGROUND Cancer-specific mortality is projected to be only 1% in 15 years in approximately 75% of patients with screen-detected localized prostate cancer (LPC). Nearly 94% of patients choose treatment even though treatment damages health-related quality of life. No data are available regarding what survival benefit patients expected from treatment. OBJECTIVES A self-administered mailed surv...
متن کاملPI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells
Background: Radiotherapy and adjuvant androgen deprivation therapy have historically been the first treatment choices for prostate cancer but treatment resistance often limits the capacity to effectively manage the disease. Therefore, alternative therapeutic approaches are needed. Here, the efficacies of radiotherapy and targeting the pro-survival cell signaling components epidermal growth fact...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of family medicine
دوره 14 3 شماره
صفحات -
تاریخ انتشار 2016